Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stress Disorders, Post-Traumatic | 44 | 2021 | 4640 | 3.560 |
Why?
|
Pregnanolone | 12 | 2021 | 67 | 2.700 |
Why?
|
Neuropeptide Y | 8 | 2017 | 194 | 1.330 |
Why?
|
Progesterone | 7 | 2021 | 752 | 1.080 |
Why?
|
Tobacco Use Disorder | 4 | 2023 | 708 | 1.080 |
Why?
|
Neurotransmitter Agents | 4 | 2018 | 663 | 1.030 |
Why?
|
Menstrual Cycle | 8 | 2021 | 546 | 0.940 |
Why?
|
Dehydroepiandrosterone | 7 | 2018 | 259 | 0.940 |
Why?
|
Follicular Phase | 5 | 2021 | 143 | 0.940 |
Why?
|
Luteal Phase | 5 | 2021 | 138 | 0.940 |
Why?
|
Steroids | 2 | 2018 | 938 | 0.810 |
Why?
|
Exercise Therapy | 2 | 2020 | 939 | 0.740 |
Why?
|
Dissociative Disorders | 6 | 2016 | 235 | 0.710 |
Why?
|
Smoking Cessation | 3 | 2023 | 2085 | 0.680 |
Why?
|
Stress, Psychological | 13 | 2017 | 4530 | 0.630 |
Why?
|
Hydrocortisone | 13 | 2012 | 1841 | 0.610 |
Why?
|
Dehydroepiandrosterone Sulfate | 5 | 2018 | 241 | 0.580 |
Why?
|
Pituitary-Adrenal System | 5 | 2021 | 555 | 0.570 |
Why?
|
Hypothalamo-Hypophyseal System | 5 | 2021 | 702 | 0.530 |
Why?
|
Endophenotypes | 1 | 2018 | 258 | 0.530 |
Why?
|
Sweat Glands | 1 | 2016 | 33 | 0.530 |
Why?
|
Stress, Physiological | 8 | 2016 | 1408 | 0.520 |
Why?
|
Premenstrual Syndrome | 1 | 2016 | 111 | 0.510 |
Why?
|
Habituation, Psychophysiologic | 1 | 2016 | 147 | 0.500 |
Why?
|
Rape | 1 | 2016 | 131 | 0.490 |
Why?
|
Neuroanatomy | 1 | 2015 | 73 | 0.470 |
Why?
|
Body Temperature Regulation | 1 | 2016 | 292 | 0.470 |
Why?
|
Hormones | 1 | 2018 | 870 | 0.460 |
Why?
|
Panic Disorder | 2 | 2016 | 613 | 0.460 |
Why?
|
Galvanic Skin Response | 1 | 2016 | 359 | 0.450 |
Why?
|
Neurobiology | 1 | 2015 | 135 | 0.450 |
Why?
|
Sympathetic Nervous System | 1 | 2016 | 521 | 0.430 |
Why?
|
Neuropeptides | 1 | 2018 | 951 | 0.410 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2016 | 301 | 0.400 |
Why?
|
Phobic Disorders | 1 | 2015 | 441 | 0.400 |
Why?
|
5-alpha-Dihydroprogesterone | 3 | 2018 | 5 | 0.390 |
Why?
|
Irritable Bowel Syndrome | 1 | 2017 | 454 | 0.370 |
Why?
|
Combat Disorders | 3 | 2017 | 301 | 0.360 |
Why?
|
Fluoxetine | 3 | 2012 | 733 | 0.350 |
Why?
|
Yohimbine | 3 | 2003 | 62 | 0.340 |
Why?
|
Adrenergic alpha-Antagonists | 2 | 2000 | 173 | 0.320 |
Why?
|
Receptors, GABA-A | 3 | 2018 | 625 | 0.320 |
Why?
|
Hydroxysteroid Dehydrogenases | 2 | 2018 | 30 | 0.310 |
Why?
|
Fear | 9 | 2021 | 1493 | 0.310 |
Why?
|
Disability Evaluation | 1 | 2016 | 1839 | 0.310 |
Why?
|
Veterans | 9 | 2019 | 2672 | 0.260 |
Why?
|
Pain | 1 | 2020 | 5100 | 0.250 |
Why?
|
Sex Characteristics | 1 | 2015 | 2649 | 0.240 |
Why?
|
Depressive Disorder | 3 | 2016 | 3723 | 0.240 |
Why?
|
Comorbidity | 9 | 2018 | 10592 | 0.230 |
Why?
|
Anxiety | 4 | 2021 | 4672 | 0.230 |
Why?
|
Smoking | 3 | 2023 | 9094 | 0.230 |
Why?
|
Health Status | 1 | 2016 | 4095 | 0.210 |
Why?
|
Adult | 42 | 2021 | 223851 | 0.210 |
Why?
|
Adrenal Glands | 1 | 2004 | 557 | 0.190 |
Why?
|
Extinction, Psychological | 2 | 2016 | 367 | 0.190 |
Why?
|
Dentate Gyrus | 1 | 2002 | 165 | 0.190 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2006 | 628 | 0.180 |
Why?
|
Affect | 3 | 2013 | 1500 | 0.180 |
Why?
|
Female | 39 | 2021 | 397515 | 0.180 |
Why?
|
Humans | 61 | 2023 | 768970 | 0.170 |
Why?
|
United States Department of Veterans Affairs | 2 | 2015 | 941 | 0.160 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2018 | 21 | 0.160 |
Why?
|
Psychiatric Status Rating Scales | 9 | 2017 | 6030 | 0.160 |
Why?
|
Exercise | 1 | 2016 | 5954 | 0.160 |
Why?
|
Tourette Syndrome | 3 | 1997 | 400 | 0.160 |
Why?
|
GABA Agents | 1 | 2018 | 41 | 0.150 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 2 | 2021 | 903 | 0.150 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2002 | 605 | 0.150 |
Why?
|
Receptors, Adrenergic, alpha-2 | 1 | 1998 | 69 | 0.150 |
Why?
|
Androstane-3,17-diol | 1 | 2017 | 20 | 0.150 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2018 | 354 | 0.150 |
Why?
|
Male | 37 | 2021 | 365203 | 0.150 |
Why?
|
Mood Disorders | 1 | 2004 | 1129 | 0.140 |
Why?
|
Glucocorticoids | 3 | 2017 | 2167 | 0.140 |
Why?
|
Premenopause | 1 | 2001 | 1039 | 0.140 |
Why?
|
Cues | 1 | 2002 | 878 | 0.140 |
Why?
|
Midwestern United States | 1 | 2016 | 70 | 0.130 |
Why?
|
Military Personnel | 6 | 2019 | 1264 | 0.130 |
Why?
|
Receptors, GABA | 1 | 2018 | 312 | 0.130 |
Why?
|
Pilot Projects | 3 | 2018 | 8748 | 0.120 |
Why?
|
Ghrelin | 1 | 2017 | 251 | 0.120 |
Why?
|
8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1994 | 32 | 0.120 |
Why?
|
Down-Regulation | 1 | 2002 | 2942 | 0.120 |
Why?
|
Substance Abuse Detection | 1 | 2018 | 301 | 0.120 |
Why?
|
Infrared Rays | 1 | 2016 | 249 | 0.120 |
Why?
|
Tryptophan | 1 | 1997 | 482 | 0.120 |
Why?
|
Affective Symptoms | 1 | 2017 | 418 | 0.120 |
Why?
|
Young Adult | 10 | 2021 | 60131 | 0.120 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2021 | 1141 | 0.120 |
Why?
|
Brain Injuries | 2 | 2019 | 2058 | 0.120 |
Why?
|
Afghan Campaign 2001- | 1 | 2015 | 298 | 0.110 |
Why?
|
Thinness | 1 | 2017 | 483 | 0.110 |
Why?
|
Serotonin Receptor Agonists | 1 | 1994 | 151 | 0.110 |
Why?
|
Gastric Mucosa | 1 | 2017 | 602 | 0.110 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2014 | 88 | 0.110 |
Why?
|
Middle Aged | 17 | 2021 | 223737 | 0.100 |
Why?
|
Carbon Dioxide | 1 | 2016 | 1149 | 0.100 |
Why?
|
Constipation | 1 | 2017 | 570 | 0.100 |
Why?
|
Depression | 5 | 2017 | 8231 | 0.100 |
Why?
|
Cross-Over Studies | 2 | 2017 | 2108 | 0.100 |
Why?
|
Pain Threshold | 1 | 2016 | 606 | 0.100 |
Why?
|
Menopause | 1 | 2019 | 1656 | 0.090 |
Why?
|
Potassium Channels | 1 | 2014 | 538 | 0.090 |
Why?
|
Case-Control Studies | 4 | 2016 | 22296 | 0.090 |
Why?
|
Saliva | 5 | 2012 | 854 | 0.090 |
Why?
|
Prefrontal Cortex | 4 | 1999 | 2237 | 0.090 |
Why?
|
Obsessive-Compulsive Disorder | 2 | 1997 | 1508 | 0.090 |
Why?
|
Valproic Acid | 1 | 2013 | 444 | 0.090 |
Why?
|
Conditioning, Classical | 1 | 2013 | 368 | 0.090 |
Why?
|
Severity of Illness Index | 7 | 2018 | 15951 | 0.090 |
Why?
|
Police | 1 | 2012 | 158 | 0.090 |
Why?
|
Diarrhea | 1 | 2017 | 1320 | 0.090 |
Why?
|
Estradiol | 1 | 2017 | 1952 | 0.080 |
Why?
|
Double-Blind Method | 5 | 2017 | 12467 | 0.080 |
Why?
|
Behavior, Animal | 3 | 2012 | 1862 | 0.080 |
Why?
|
Up-Regulation | 2 | 2012 | 4148 | 0.080 |
Why?
|
Animals | 14 | 2017 | 169335 | 0.080 |
Why?
|
Anorexia Nervosa | 1 | 2017 | 1364 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 778 | 0.080 |
Why?
|
Brain | 4 | 2019 | 27453 | 0.080 |
Why?
|
tau Proteins | 1 | 2019 | 2146 | 0.070 |
Why?
|
Disease Models, Animal | 3 | 2012 | 18354 | 0.070 |
Why?
|
Exercise Test | 1 | 2016 | 2187 | 0.070 |
Why?
|
Guanfacine | 1 | 2008 | 50 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2018 | 5323 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2002 | 12806 | 0.070 |
Why?
|
Brain Concussion | 1 | 2019 | 1436 | 0.070 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 1 | 2008 | 92 | 0.070 |
Why?
|
Psychotherapy | 1 | 2016 | 1654 | 0.070 |
Why?
|
Overweight | 1 | 2017 | 2448 | 0.070 |
Why?
|
Self Report | 1 | 2018 | 3773 | 0.070 |
Why?
|
Pituitary-Adrenal Function Tests | 2 | 2003 | 30 | 0.060 |
Why?
|
Substance-Related Disorders | 2 | 2018 | 4423 | 0.060 |
Why?
|
Cosyntropin | 1 | 2004 | 34 | 0.060 |
Why?
|
Testosterone | 2 | 2017 | 2493 | 0.060 |
Why?
|
Executive Function | 1 | 2013 | 1405 | 0.060 |
Why?
|
Urban Population | 2 | 2003 | 2046 | 0.060 |
Why?
|
Dietary Carbohydrates | 1 | 2009 | 896 | 0.060 |
Why?
|
Depressive Disorder, Major | 2 | 2018 | 4818 | 0.060 |
Why?
|
Antidepressive Agents | 1 | 2016 | 2913 | 0.060 |
Why?
|
Nicotinic Agonists | 1 | 2006 | 265 | 0.060 |
Why?
|
Corticotropin-Releasing Hormone | 2 | 2003 | 360 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 1313 | 0.050 |
Why?
|
Adrenocorticotropic Hormone | 2 | 2003 | 619 | 0.050 |
Why?
|
Emotions | 2 | 2012 | 2768 | 0.050 |
Why?
|
Adolescent | 8 | 2018 | 89244 | 0.050 |
Why?
|
Norepinephrine | 3 | 2002 | 899 | 0.050 |
Why?
|
Catecholamines | 2 | 2001 | 389 | 0.050 |
Why?
|
Serotonin | 3 | 1999 | 1043 | 0.050 |
Why?
|
Analysis of Variance | 3 | 2006 | 6236 | 0.050 |
Why?
|
20-alpha-Dihydroprogesterone | 1 | 2001 | 2 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6673 | 0.050 |
Why?
|
Biomedical Research | 1 | 2018 | 3463 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 5 | 2002 | 8144 | 0.050 |
Why?
|
Acoustic Stimulation | 2 | 2005 | 1256 | 0.050 |
Why?
|
Behavior | 1 | 2004 | 543 | 0.050 |
Why?
|
Cognition Disorders | 2 | 2009 | 3985 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4413 | 0.050 |
Why?
|
Task Performance and Analysis | 3 | 2013 | 771 | 0.050 |
Why?
|
Teaching | 1 | 2009 | 1171 | 0.050 |
Why?
|
Nicotine | 1 | 2006 | 680 | 0.050 |
Why?
|
Avoidance Learning | 1 | 2002 | 248 | 0.040 |
Why?
|
Child Abuse, Sexual | 1 | 2003 | 401 | 0.040 |
Why?
|
Methoxyhydroxyphenylglycol | 1 | 2000 | 93 | 0.040 |
Why?
|
Social Behavior Disorders | 1 | 2000 | 100 | 0.040 |
Why?
|
Arousal | 2 | 2003 | 1183 | 0.040 |
Why?
|
Antipsychotic Agents | 1 | 2013 | 3081 | 0.040 |
Why?
|
Survival | 1 | 2000 | 160 | 0.040 |
Why?
|
Dopamine | 2 | 1999 | 1596 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4940 | 0.040 |
Why?
|
Afghanistan | 1 | 2019 | 78 | 0.040 |
Why?
|
Iraq | 1 | 2019 | 93 | 0.040 |
Why?
|
Social Isolation | 1 | 2001 | 366 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2017 | 26395 | 0.040 |
Why?
|
Fluvoxamine | 1 | 1998 | 78 | 0.040 |
Why?
|
Repression-Sensitization | 1 | 1997 | 1 | 0.040 |
Why?
|
Life Change Events | 3 | 2012 | 961 | 0.040 |
Why?
|
Estrogens | 1 | 2004 | 1536 | 0.040 |
Why?
|
Electric Stimulation | 1 | 2002 | 1742 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2021 | 997 | 0.030 |
Why?
|
Prospective Studies | 2 | 2020 | 54962 | 0.030 |
Why?
|
Mice | 4 | 2013 | 82072 | 0.030 |
Why?
|
Rats | 5 | 2002 | 23786 | 0.030 |
Why?
|
Biogenic Monoamines | 1 | 1996 | 50 | 0.030 |
Why?
|
Breath Tests | 1 | 2018 | 300 | 0.030 |
Why?
|
Dexamethasone | 1 | 2003 | 1965 | 0.030 |
Why?
|
Aged | 7 | 2019 | 171786 | 0.030 |
Why?
|
Urinalysis | 1 | 2018 | 370 | 0.030 |
Why?
|
Blast Injuries | 1 | 2019 | 324 | 0.030 |
Why?
|
Heart Rate | 2 | 2012 | 4217 | 0.030 |
Why?
|
Sertraline | 1 | 2016 | 209 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1197 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 12801 | 0.030 |
Why?
|
Telephone | 1 | 2018 | 630 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9499 | 0.030 |
Why?
|
Violence | 1 | 2000 | 936 | 0.030 |
Why?
|
United States | 4 | 2015 | 73186 | 0.030 |
Why?
|
Pyrrolidinones | 1 | 1994 | 116 | 0.030 |
Why?
|
Butyric Acid | 1 | 2013 | 52 | 0.030 |
Why?
|
Dopamine Antagonists | 1 | 1994 | 284 | 0.030 |
Why?
|
Neuronal Plasticity | 1 | 2002 | 1448 | 0.030 |
Why?
|
Neurologic Examination | 1 | 1997 | 916 | 0.030 |
Why?
|
Recurrence | 1 | 2006 | 8513 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2017 | 65480 | 0.030 |
Why?
|
Nerve Degeneration | 1 | 1997 | 750 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2003 | 2666 | 0.030 |
Why?
|
Hippocampus | 2 | 2012 | 3782 | 0.030 |
Why?
|
Anti-Anxiety Agents | 1 | 1994 | 405 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2003 | 2593 | 0.020 |
Why?
|
Off-Label Use | 1 | 2013 | 185 | 0.020 |
Why?
|
Neurons | 2 | 2002 | 9519 | 0.020 |
Why?
|
Primary Health Care | 2 | 2014 | 4748 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2003 | 2517 | 0.020 |
Why?
|
Desipramine | 1 | 1991 | 183 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 904 | 0.020 |
Why?
|
Risk Factors | 4 | 2012 | 74976 | 0.020 |
Why?
|
Research Design | 1 | 2006 | 6214 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 7148 | 0.020 |
Why?
|
Death, Sudden | 1 | 1991 | 301 | 0.020 |
Why?
|
Amygdala | 1 | 1996 | 1379 | 0.020 |
Why?
|
Psychometrics | 2 | 2012 | 3066 | 0.020 |
Why?
|
Electromyography | 1 | 2012 | 1401 | 0.020 |
Why?
|
Chronic Disease | 1 | 2001 | 9384 | 0.020 |
Why?
|
Psychotic Disorders | 1 | 2001 | 3278 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2553 | 0.020 |
Why?
|
Aging | 1 | 2004 | 8745 | 0.020 |
Why?
|
Time Factors | 3 | 2013 | 40261 | 0.010 |
Why?
|
Blinking | 1 | 2005 | 135 | 0.010 |
Why?
|
Placebo Effect | 1 | 2009 | 518 | 0.010 |
Why?
|
Corticosterone | 2 | 1996 | 301 | 0.010 |
Why?
|
Blood Pressure | 1 | 2000 | 8544 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8559 | 0.010 |
Why?
|
Neurosecretory Systems | 1 | 2003 | 223 | 0.010 |
Why?
|
Problem Solving | 1 | 2004 | 443 | 0.010 |
Why?
|
Prevalence | 2 | 2014 | 15879 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1992 | 2734 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9377 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 2012 | 2749 | 0.010 |
Why?
|
Personality Inventory | 1 | 2003 | 1018 | 0.010 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2001 | 186 | 0.010 |
Why?
|
Connecticut | 1 | 2000 | 365 | 0.010 |
Why?
|
Mental Health | 1 | 2014 | 3275 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13055 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7861 | 0.010 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 1999 | 153 | 0.010 |
Why?
|
Placebos | 1 | 2003 | 1667 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10400 | 0.010 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1999 | 177 | 0.010 |
Why?
|
Poverty Areas | 1 | 2000 | 269 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2021 | 81903 | 0.010 |
Why?
|
Epinephrine | 1 | 2002 | 794 | 0.010 |
Why?
|
Oxidopamine | 1 | 1999 | 170 | 0.010 |
Why?
|
Adrenergic Agents | 1 | 1999 | 72 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 36854 | 0.010 |
Why?
|
Child | 6 | 2005 | 80960 | 0.010 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 1999 | 430 | 0.010 |
Why?
|
Stereoisomerism | 1 | 1998 | 611 | 0.010 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 1 | 1996 | 60 | 0.010 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2003 | 1988 | 0.010 |
Why?
|
Akathisia, Drug-Induced | 1 | 1997 | 66 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2012 | 14794 | 0.010 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 1991 | 3730 | 0.010 |
Why?
|
Regression Analysis | 1 | 2004 | 6346 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 16053 | 0.010 |
Why?
|
Acute Disease | 1 | 2004 | 7245 | 0.010 |
Why?
|
Adolescent Behavior | 1 | 2000 | 1188 | 0.010 |
Why?
|
Nucleus Accumbens | 1 | 1994 | 358 | 0.010 |
Why?
|
Cognition | 1 | 2009 | 7081 | 0.010 |
Why?
|
Glycine | 1 | 1994 | 672 | 0.010 |
Why?
|
Recovery of Function | 1 | 2001 | 2990 | 0.010 |
Why?
|
Memory | 1 | 1999 | 2209 | 0.010 |
Why?
|
Ventricular Fibrillation | 1 | 1991 | 537 | 0.000 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1992 | 1141 | 0.000 |
Why?
|
Heart Arrest | 1 | 1991 | 1515 | 0.000 |
Why?
|